AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37380156
Drug: ANDV DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANDV DNA vaccine (2 mg) in a 3-dose schedule (days 1, 29, 169)
Trial: 37380156
Drug: ANDV DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANDV DNA vaccine (2 mg) in a 4-dose schedule (days 1, 29, 57, 169)
Trial: 37380156
Drug: ANDV DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANDV DNA vaccine (4 mg) in a 3-dose schedule (days 1, 29, 169)
Trial: 37380156
Drug: ANDV DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANDV DNA vaccine (4 mg) in a 4-dose schedule (days 1, 29, 57, 169)
Trial: 37380211
Drug: TESLA-G (gamified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TESLA-G (gamified quizzing platform)
Trial: 37380211
Drug: TESLA-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TESLA-G
Trial: 37380226
Drug: Transcatheter edge-to-edge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter edge-to-edge repair (TEER) plus guideline-directed medical therapy (GDMT)
Trial: 37380226
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy (GDMT) alone without anticoagulation
Trial: 37380364
Drug: Roxadustat (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (oral hypoxia-inducible factor prolyl hydroxylase inhibitor), administered three times weekly in-center for 24 weeks.
Trial: 37380821
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion using vascular access button (VAB) technology for AZD5991
Trial: 37381988
Drug: rNAPc2 (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rNAPc2 (lower or higher dose)
Trial: 37381988
Drug: Heparin (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (standard of care)
Trial: 37382155
Drug: mRNA vaccines
RxNorm normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA vaccines BNT162b2 (Pfizer/BioNTech), mRNA1273 (Moderna) in two and three-dose regimens
Trial: 37382155
Drug: Bivalent mRNA
RxNorm normalized name: Adult B and BA.4/BA.5 lineage SARS-CoV-2 bivalent mRNA only vaccine product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent mRNA vaccines
Trial: 37382155
Drug: Individualization and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualization and adjustment of immunosuppressive drugs
Trial: 37382794
Drug: FM-ACT (self-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FM-ACT (self-guided digital acceptance and commitment therapy) for 12 weeks, n=39
Trial: 37383763
Drug: Standard opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard opioid prescription (ten 5 mg tablets oxycodone provided preoperatively)
Trial: 37383763
Drug: Restricted opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted opioid prescription (opioid prescription provided only upon patient request postoperatively)
Trial: 37383995
Drug: Wheat soya
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat soya blend plus (WSB+) during pregnancy and first six months of lactation, and lipid-based nutrient supplement - medium-quantity (LNS-MQ) between 6-23 months of age.
Trial: 37384109
Drug: Probiotic and
RxNorm normalized name: Florastor Advanced Probiotic And Digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic and herbal supplement taken twice a day for 1 month
Trial: 37384278
Drug: Microburst VNS
RxNorm normalized name: VN-rzyl
DrugBank: Voretigene neparvovec (DB13932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microburst VNS in addition to standard anti-seizure medications
Trial: 37384412
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg twice daily for 6 weeks
Trial: 37384482
Drug: Concurrent Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders using Seeking Safety
Trial: 37384482
Drug: Concurrent Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders (both interventions)
Trial: 37384848
Drug: Zipalertinib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zipalertinib at various dose levels (30, 45, 65, 100, and 150 mg orally twice a day)
Trial: 37384848
Drug: Zipalertinib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zipalertinib at 100 mg twice a day
Trial: 37385272
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant VWF, 40 IU/kg over 5-10 min on day 1
Trial: 37385272
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid 1300 mg three times daily on days 1-5
Trial: 37385279
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 50 mg
Trial: 37385279
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 25 mg
Trial: 37385280
Drug: Retatrutide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retatrutide 0.5 mg
Trial: 37385280
Drug: Retatrutide 4
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retatrutide 4 mg escalation
Trial: 38858523
Drug: Retatrutide 4
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retatrutide 4 mg
Trial: 37385280
Drug: Retatrutide 8
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retatrutide 8 mg slow escalation
Trial: 37385280
Drug: Retatrutide 8
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retatrutide 8 mg fast escalation
Trial: 37385280
Drug: Retatrutide 12
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retatrutide 12 mg escalation
Trial: 37385475
Drug: JNJ-56136379 75
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 75 mg monotherapy
Trial: 37385475
Drug: JNJ-56136379 250
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 250 mg monotherapy
Trial: 37385724
Drug: SEA-CD40 administered
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEA-CD40 administered intravenously at doses of 0.6, 3, 10, 30, 45, and 60 µg/kg in 21-day cycles.
Trial: 37385724
Drug: SEA-CD40 administered
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEA-CD40 administered intravenously at doses of 10-30 µg/kg.
Trial: 37385724
Drug: SEA-CD40 monotherapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEA-CD40 monotherapy.
Trial: 37385747
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) - combination of aspirin and P2Y
Trial: 37386016
Drug: Milademetan (MDM2i)
RxNorm normalized name: Milademetan
DrugBank: Milademetan (DB15257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milademetan (MDM2i) with low-dose cytarabine (LDAC)
Trial: 37386016
Drug: Milademetan (MDM2i)
RxNorm normalized name: Milademetan
DrugBank: Milademetan (DB15257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milademetan (MDM2i) with low-dose cytarabine (LDAC)±venetoclax
Trial: 37386368
Drug: Physical therapy-led
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy-led triage
Trial: 37386462
Drug: Antipsychotic-naïve and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic-naïve and previously medicated participants
Trial: 37386519
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anesthesia with 40 mg of hyperbaric prilocaine (Group A)
Trial: 37386582
Drug: Deep neuromuscular
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep neuromuscular block (DNMB) with rocuronium bolus at 1.2 mg/kg and maintenance dose of 0.3-0.6 mg/kg/h
Trial: 37386582
Drug: Moderate neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate neuromuscular block (MNMB) with rocuronium bolus at 0.6 mg/kg and maintenance dose in boluses of 0.15-0.25 mg/kg
Trial: 37387798
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine administration at 1.5 mg/kg
Trial: 37388233
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy (HF-RT) - 40 Gy/15 fractions ± concomitant boost [8 Gy/15 fractions]
Trial: 37388233
Drug: Conventional fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionated radiation therapy (CF-RT) - 50 Gy/25 fractions ± sequential boost [10 Gy/5 fractions]
Trial: 37388633
Drug: Flexitarian diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexitarian diet including approximately three serves of red meat (average of 390 g cooked weight per individual) per week
Trial: 37388633
Drug: Vegetarian diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetarian diet including plant-based meat alternatives (350-400 g per individual) per week
Trial: 37388902
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICIs) treatment in EGFR-mutant NSCLC patients with YAP1_High expression
Trial: 37388902
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICIs) treatment in EGFR-mutant NSCLC patients with YAP1_Low expression
Trial: 37389891
Drug: Bezlotoxumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezlotoxumab (10 mg/kg)
Trial: 37389915
Drug: Purposeful Pathways
RxNorm normalized name: Corona Multi-Purpose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purposeful Pathways intervention (augmented treatment condition)
Trial: 37390800
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ctDNA MAF and carcinoembryonic antigen levels
Trial: 37390836
Drug: ZPIV (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPIV (two or three doses administered at days 0, 28, and 196-234)
Trial: 37390836
Drug: ZPIV (third
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPIV (third dose)
Trial: 37390836
Drug: ZPIV (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPIV (two doses)
Trial: 37390980
Drug: Durvalumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab plus Olaparib (300 mg orally, twice daily)
Trial: 37391367
Drug: Daily written
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily written patient care updates
Trial: 37391381
Drug: Rapid steroid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid steroid withdrawal (RSWD)
Trial: 37391381
Drug: Standard immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppressive therapy
Trial: 37391938
Drug: Anti-EGFR rechallenge
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-EGFR rechallenge (fourth-line therapy)
Trial: 37391938
Drug: Other therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other therapies (fourth-line therapy)
Trial: 37391938
Drug: Anti-EGFR rechallenge
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-EGFR rechallenge (fourth-line treatment)
Trial: 37391938
Drug: Other therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other therapies (fourth-line treatment)
Trial: 37392089
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine (twice-a-week for 4 weeks, then once-a-week for 4 weeks)
Trial: 37392789
Drug: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) 160/150/50 μg, once-daily (o.d.)
Trial: 37392789
Drug: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) pooled (160/150/50 μg and 80/150/50 μg)
Trial: 37392789
Drug: High-dose Mometasone/indacaterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Mometasone/indacaterol (MF/IND) 320/150 μg, once-daily (o.d.)
Trial: 37392789
Drug: High-dose Fluticasone/salmeterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Fluticasone/salmeterol (FLU/SAL) 500/50 μg, twice-daily (b.i.d.)
Trial: 37393237
Drug: Adjuvanted inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted inactivated influenza vaccine (aIIV3)
Trial: 37393237
Drug: High-dose inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inactivated influenza vaccine (HD-IIV3)
Trial: 37393658
Drug: Adrenocorticotropic hormone
RxNorm normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenocorticotropic hormone (ACTH) stimulation
Trial: 37393691
Drug: Interference testing
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interference testing of over-the-counter and common co-administered medications.
Trial: 37393762
Drug: KN046 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN046 3 mg/kg
Trial: 37393762
Drug: KN046 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN046 5 mg/kg
Trial: 37394178
Drug: FMXIN002 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMXIN002 3.2 mg after nasal allergen challenge
Trial: 37394627
Drug: Adavosertib (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (225 mg bid) co-administration with cocktail
Trial: 37394920
Drug: BMS-986141, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986141, a novel, oral, PAR4 agonist, administered as a single ascending dose.
Trial: 37395169
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment applied to each foot once a week for four weeks (n=16)
Trial: 37395185
Drug: Activated recombinant
RxNorm normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated recombinant FVII (rFVIIa) at a recommended dose of 15-30 μg/kg
Trial: 37395254
Drug: Integrase-strand transfer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrase-strand transfer inhibitors (INSTIs)
Trial: 37395948
Drug: Ultrasound-guided dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided dextrose hydrodissection (1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 1% normal saline)
Trial: 37395974
Drug: Amlodipine, Losartan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine, Losartan, Rosuvastatin, and Ezetimibe (A/L/R/E)
Trial: 37395974
Drug: Amlodipine and
RxNorm normalized name: amlodipine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine and Losartan (A/L)
Trial: 37395974
Drug: Losartan, Rosuvastatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan, Rosuvastatin, and Ezetimibe (L/R/E)
Trial: 37396126
Drug: Innovative synbiotics
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovative synbiotics treatment for CKD patients
Trial: 37397078
Drug: Remote Ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Ischemic Conditioning (RIC) - 3 cycles of 5-minute inflation of a blood pressure cuff to 15 mm Hg above systolic pressure before anthracycline therapy
Trial: 37397433
Drug: Integrated pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Integrated pharmaceutical care at psychosocial intervention
Trial: 37397983
Drug: PPM-guided dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPM-guided dosing of tacrolimus
Trial: 37397983
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) clinician-determined dosing of tacrolimus
Trial: 37398043
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hrHPV testing followed by Gynocular
Trial: 37398623
Drug: Elagolix 25
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix 25 mg twice daily
Trial: 37398623
Drug: Elagolix 50
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix 50 mg once daily
Trial: 37398623
Drug: Elagolix 75
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix 75 mg twice daily
Trial: 37398623
Drug: Elagolix 300
RxNorm normalized name: elagolix 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix 300 mg twice daily
Trial: 37398623
Drug: Elagolix (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix (all doses)
Trial: 37398992
Drug: Ganitumab 18
RxNorm normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganitumab 18 mg/kg intravenously every 2 weeks and Dasatinib 60 mg/m2/dose (max 100 mg) oral once daily (DL1)
Trial: 37398992
Drug: Ganitumab 18
RxNorm normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganitumab 18 mg/kg intravenously every 2 weeks and Dasatinib 60 mg/m2/dose (max 70 mg) twice daily (DL2)
Trial: 37398992
Drug: Ganitumab 18
RxNorm normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganitumab 18 mg/kg every 2 weeks and Dasatinib 60 mg/m2/dose daily
Trial: 37399456
Drug: Defibrotide (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (6.25 mg/kg)
Trial: 37399757
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) augmentation of exposure-based CBT
Trial: 37399757
Drug: Exposure-based CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based CBT without DCS augmentation
Trial: 37400353
Drug: Bacillus Calmette-Guérin
RxNorm normalized name: Bacillus Calmette-Guérin (BCG) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guérin (BCG) therapy
Trial: 37400432
Drug: Stanford Neuromodulation
RxNorm normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stanford Neuromodulation Therapy (SNT)
Trial: 37400758
Drug: Pharmacist-led deprescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led deprescribing intervention (education of health care personnel, access to standardized discontinuation regimens, patient education, support of transitional care)
Trial: 37400806
Drug: Circulating DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating DNA (cDNA) detection before potentiated radiotherapy and at 3 months post-treatment.
Trial: 37400812
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (Sb) 600 mg orally once daily for eight days
Trial: 37400844
Drug: FCN-159 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-159 8 mg
Trial: 37400844
Drug: FCN-159 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-159 12 mg
Trial: 37400844
Drug: FCN-159 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-159 (all doses)
Trial: 37400849
Drug: Resin infiltration
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin infiltration treatment (Icon®) applied to hypomineralised enamel lesions
Trial: 37400849
Drug: Resin infiltration
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin infiltration treatment (Icon®)
Trial: 37401618
Drug: MPV-4 (quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPV-4 (quadrivalent meningococcal polysaccharide vaccine)
Trial: 37401618
Drug: MCV-4 (quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCV-4 (quadrivalent meningococcal conjugate vaccine, Menactra®)
Trial: 37401774
Drug: SARS-CoV-2 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 antibodies